SAN DIEGO, Feb. 24, 2020
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today
announced that Elaine D. Sun has
been appointed senior vice president and chief financial officer,
effective March 2, 2020. Ms. Sun will
succeed Laurie Stelzer, who has
resigned to pursue another opportunity.
Ms. Sun brings more than two decades of experience in the
investment banking and life sciences industries to Halozyme. Over
her career she has led and played key roles in a broad range of
transactions, including multiple mergers, acquisitions and
financings, valued in excess of $50
billion. She most recently served as chief financial officer
and chief strategy officer at SutroVax, Inc., a private
biopharmaceutical company developing vaccines to prevent serious
infectious diseases. While at SutroVax she provided strategic,
operational and financial leadership for a rapidly growing
organization, including establishing innovative agreements with
external contract manufacturers. Previously, Ms. Sun served as
Managing Director and Head of West Coast Healthcare for Evercore
Partners and Managing Director at Merrill Lynch & Co., Inc. Ms.
Sun currently serves on the board of directors of Cirius
Therapeutics, a clinical-stage pharmaceutical company. Ms. Sun
received her B.A. from Wellesley
College and M.B.A from Harvard Business
School.
"Elaine is a strong addition to our leadership team," said Dr.
Helen Torley, president and chief
executive officer. "With Elaine's contributions, we look forward to
capitalizing on our future business opportunities and delivering
additional value to shareholders. On behalf of the Board, I want to
thank Laurie for her contributions to Halozyme and wish her all the
best in her future endeavors."
"I am delighted to join Halozyme at such an exciting time in the
company's evolution," said Ms. Sun. "I look forward to working
closely with Helen and the rest of the team at Halozyme to drive
growth, profitability and value creation for shareholders."
About Halozyme
Halozyme Therapeutics is a biotechnology
company focused on novel biological and drug
delivery approaches. Halozyme's proprietary enzyme
rHuPH20 is used to facilitate the delivery of
injected drugs and fluids and potentially
reduce the treatment burden of other drugs
to patients. Halozyme has licensed its
rHuPH20 technology, called ENHANZE®, to leading
pharmaceutical and biotechnology companies including
Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb, Alexion and argenx.
Halozyme derives
revenues from these collaborations in
the form of milestones and royalties as
the Company's partners make progress developing and
commercializing their products being developed with
ENHANZE®. Halozyme is headquartered in San Diego.
For more information visit
www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements including, without
limitation, statements concerning the Company's future financial
performance including expectations for profitability and reduced
expenses, plans to implement an organizational restructuring
including anticipated reductions in employee headcount, plans to
focus its operations solely on its ENHANZE® drug
delivery technology, and the Company's plans to continue to execute
on its share repurchase program. Forward-looking statements
regarding the Company's ENHANZE® drug delivery
technology may include potential growth of the ENHANZE®
business, the possible activity, benefits and attributes of
ENHANZE®, the possible method of action of
ENHANZE®, its potential application to aid in the
dispersion and absorption of other injected therapeutic drugs, the
number of collaborative targets actually chosen, whether such
products are ultimately developed or commercialized, whether
milestones triggering milestone payments will be achieved, and
statements concerning facilitating more rapid delivery of
injectable medications through subcutaneous delivery that involve
risk and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. The
forward-looking statements are typically, but not always,
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including unexpected fluctuations or changes in revenues, including
revenues from collaborators, unexpected delays or results of the
Company's organizational restructuring, unexpected expenditures and
costs, unexpected delays in the execution of the planned share
repurchase, unexpected results or delays in the growth of the
Company's ENHANZE® business, unexpected results or
delays in the development and regulatory review of
ENHANZE® products, regulatory approval requirements,
unexpected adverse events and competitive conditions.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate
Communications 858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-cfo-transition-301010030.html
SOURCE Halozyme Therapeutics, Inc.